HER2-Positive Breast Cancer Medical Services in China

HER2-positive breast cancer is an aggressive subtype characterized by overexpression or amplification of the human epidermal growth factor receptor 2 (HER2) protein, detected via immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Accounting for approximately 15–20% of invasive breast cancers, it exhibits rapid proliferation, higher recurrence risk, and poorer prognosis without targeted intervention. However, the advent of HER2-directed therapies—including monoclonal antibodies (tr pertuzumab), antibody-drug conjugates (fam-trastuzumab deruxtecan-nxki), and tyrosine kinase inhibitors (lapatinib, tucatinib)—has transformed outcomes, significantly improving progression-free and overall survival, especially when integrated into neoadjuvant, adjuvant, or metastatic treatment regimens.

China offers compelling advantages for international patients seeking HER2-positive breast cancer care. Leading oncology centers—such as Fudan University Shanghai Cancer Center and Sun Yat-sen University Cancer Center—host nationally certified HER2 testing laboratories and multidisciplinary tumor boards with extensive experience in complex cases. Advanced imaging (3.0T MRI, digital PET-CT), robotic-assisted surgery, and early access to globally approved biologics—including biosimilar trastuzumab with equivalent efficacy and safety profiles—enhance therapeutic precision. Clinical outcomes align with international benchmarks: five-year disease-free survival exceeds 85% in early-stage patients receiving guideline-concordant dual HER2 blockade. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising quality—drugs, diagnostics, and hospital stays remain rigorously regulated by China’s National Medical Products Administration (NMPA).

As a dedicated medical tourism agency, we facilitate seamless cross-border care: verifying hospital accreditation, coordinating appointments with certified oncologists, providing itemized, transparent pricing in advance, arranging visa support, interpreters, accommodation, and post-treatment follow-up—all tailored to individual clinical and logistical needs.

China offers a compelling option for HER2-positive breast cancer treatment, combining advanced oncology care with significant cost advantages. Treatment costs—including targeted therapies like trastuzumab and pertuzumab, plus comprehensive diagnostics and multidisciplinary care—are typically 40–60% lower than in the U.S. or Western Europe, without compromising clinical standards. Leading Chinese cancer centers, such as Fudan University Shanghai Cancer Center and Sun Yat-sen University Cancer Center, utilize state-of-the-art PET-CT, digital pathology platforms, and next-generation sequencing for precise HER2 assessment and treatment personalization. These institutions have extensive experience managing HER2-positive cases, participating in global clinical trials and adhering to NCCN and ESMO guidelines. As a medical tourism agency, we provide transparent, itemized pricing upfront, assist in selecting accredited hospitals based on your clinical profile and preferences, and support budget planning—including estimated out-of-pocket costs and timeline-based financial projections. The treatment process is streamlined: pre-arrival document review, coordinated appointments with oncologists and surgeons, real-time translation, and post-treatment follow-up coordination. All services are designed to reduce administrative burden while maintaining clinical rigor and continuity of care.

The international patient treatment process for HER2-positive breast cancer begins with a remote consultation: patients submit medical records (pathology reports, imaging, prior treatment summaries) for oncology review. Our agency schedules specialist appointments within 3–5 business days, coordinates English-speaking oncologists and translators, and arranges airport transfers and verified accommodation near the hospital. Upon arrival, patients undergo confirmatory diagnostics (e.g., IHC/FISH retesting, staging scans) and multidisciplinary tumor board review. Treatment—typically neoadjuvant or adjuvant anti-HER2 therapy (trastuzumab/pertuzumab ± chemotherapy) or T-DM1 for metastatic disease—is personalized and administered over 6–12 months, depending on stage and response. Our team provides in-person accompaniment to all consultations and procedures, real-time translation, medication guidance, and logistical support (visa letters, insurance coordination, follow-up scheduling). Required materials include ID/passport, medical records (in English), referral letter, and insurance documentation. The full process—from initial inquiry to treatment initiation—takes approximately 2–4 weeks; total treatment duration varies per protocol. All services include 24/7 multilingual support (English, Arabic, Russian, Mandarin), dedicated case management, and secure digital health record access.

Medical Travel to China Guide: HER2-Positive Breast Cancer

Most nationalities require a Chinese visa for medical treatment; we assist with the Medical Visa (Q2 or S2) application, providing invitation letters from partner hospitals and supporting documentation. Entry requires a valid passport, negative PCR test within 48 hours pre-departure (requirements subject to change—our team confirms current rules).

Medical insurance is not accepted by most Chinese hospitals for international patients; however, our agency offers transparent, all-inclusive pricing—covering diagnostics, targeted therapy (e.g., trastuzumab, pertuzumab), surgery, and follow-up consultations—with no hidden fees. We coordinate direct payments via bank transfer or credit card, and provide itemized cost breakdowns before treatment begins.

We arrange comfortable, hospital-proximate accommodations (including apartment-style options for companions) and support visa applications for one caregiver.

Post-treatment, our dedicated care coordinators manage remote follow-up: scheduling virtual oncology reviews, sharing pathology reports in English, coordinating prescription refills, and liaising with your home-country doctors for seamless continuity of care. All services are included in our patient journey package—no extra charges, no surprises.